CUTANEOUS T-CELL LYMPHOMA
Clinical trials for CUTANEOUS T-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new CUTANEOUS T-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for CUTANEOUS T-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for rare, Tough-to-Treat blood cancers
Disease control CompletedThis early-stage trial tested a combination of four drugs to see if it was safe and effective for adults with rare T-cell cancers that had returned or stopped responding to standard treatments. The study involved 26 participants and aimed to find the highest dose they could toler…
Matched conditions: CUTANEOUS T-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 03, 2026 14:43 UTC
-
Light therapy targets skin cancer lesions
Disease control CompletedThis study tested a new treatment for early-stage mycosis fungoides, a type of skin lymphoma. Ten patients applied a special ointment to their skin lesions, which was then activated by visible light twice a week for up to a year. The goal was to see if this light-activated treatm…
Matched conditions: CUTANEOUS T-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Ellen Kim, MD • Aim: Disease control
Last updated Apr 02, 2026 14:57 UTC
-
Real-World check: does approved skin cancer drug deliver?
Disease control CompletedThis study looked at how the drug mogamulizumab performed for patients with cutaneous T-cell lymphoma (CTCL) in everyday medical practice, not just in a controlled trial. It involved 100 adults in Italy who had already tried at least one other treatment. The goal was to confirm t…
Matched conditions: CUTANEOUS T-CELL LYMPHOMA
Sponsor: Fondazione Italiana Linfomi - ETS • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
New drug combo tested in High-Stakes fight against rare blood cancers
Disease control CompletedThis study tested whether adding the drug romidepsin to a stem cell transplant could better control several aggressive types of T-cell blood cancers. Researchers gave romidepsin before and after the transplant to 23 patients to find the safest dose and see if it helped. The main …
Matched conditions: CUTANEOUS T-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC